Historically, after the proof of concept1, the first evidence of the efficiency of immunotherapy was in the treatment of cutaneous melanoma with antibodies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Here, CTLA4 is linked to cutaneous melanoma.